Drug Detail

Information about Infigratinib

Generic Name	Infigratinib
IND	BGJ398
Brand Name (US)
Manufacturer	Novartis
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Development discontinued
Indications
Overall Strategy	Oncogenic Signal Path Based
Strategy	Block related tumor signal paths + Block tumor blood vessel growth
Drug Category	FGFR inhibitor

BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2. (From: Selleckchem)